A 15-acre site in Lake Success will soon host a 200,000-square-foot cell and gene therapy research hub, backed by up to $150 million in state funding. The project aims to support startups, create hundreds of jobs, and propel Long Island's life sciences sector. The hub will include a business incubator to help bring scientific discoveries to market.
BF Innovation Inc., a skin-care product developer located in Farmingdale’s Broad Hollow Bioscience Park, has joined Gov. Andrew M. Cuomo’s Start-Up NY tax-free zones program. This participation exempts the company from state and local taxes for up to 10 years and offers state income tax exemptions to its new employees for the same period. The company focuses on developing topical drug products for dermatitis and aims to double its workforce by year-end. BF Innovation is the fourth Start-Up NY participant at Farmingdale State College’s zone, joining other biotech startups.
Gov. Andrew M. Cuomo has signed a bill enabling OSI Pharmaceuticals Inc. to expand its operations at Farmingdale State College. The legislation, which passed with overwhelming support in the State Senate and Assembly, establishes the boundaries for the college's Broad Hollow Bioscience Park at 38.5 acres and allows for the construction of a third building. This new structure will house start-up companies while OSI expands into an existing building. The move is expected to create 135 jobs at the college, bolstering Long Island's biotechnology sector.
State senators have approved a bill to expand the business incubator at Farmingdale State College, a significant move aimed at boosting the local biotechnology sector. The legislation designates 38.5 acres for the Broad Hollow Bioscience Park and facilitates the construction of a third building to house start-up companies, with OSI Pharmaceuticals expanding into an existing second building. OSI, known for its lung cancer drug Tarceva, plans to create approximately 135 new jobs. The bill also exempts park tenants from state construction and procurement laws, simplifying development processes. This expansion is expected to drive economic growth and innovation in Long Island's biotechnology industry.
Long Island's push to attract biotech startups has seen mixed results. The Broad Hollow Bioscience Park, with its recent addition of a 43,000-square-foot building, aims to foster new companies. While OSI Pharmaceuticals is expanding, other firms like Helicon Therapeutics have moved away due to delays. Despite significant investment and low rent incentives, the region’s biotech sector struggles to gain traction, facing challenges such as high costs and stiff competition from established hubs.